Grant Search

Cancer Type

Keyword Search  

Categories

Grant Amount
>=

<=





Results: 39

Targeting EZH2 as a theraputic strategy in DIPG

Malignant brain tumors are the leading cause of cancer-related mortality in children (1), and diffuse intrinsic pontine glioma (DIPG) is one of the most devastating, with a median survival of <1 year following treatment with radiation therapy (2). Despite more than 250 clinical trials over the past 30 years (3), not a single chemotherapeutic agent ...

COllaborative Network for NEurooncology Clinical Trials (CONNECT)

CONNECT’s goal is to establish an international clinical trials collaboration for the conduct of scientificallrational, pilot studies to assess feasibility and early efficacy of incorporating promising novel agents testablished frontline therapeutic regimens in children with newly-diagnosed, high-risk brain tumors. Thicollaboration builds on the existing infrastructure and partnerships established ...

Elucidating the underlying mechanisms of radio resistance at diagnosis and ...

Backgound. Radiotherapy is still the mainstay of the treatment for DIPG. If the majority of children experience an improvement of their neurological condition following irradiation, this effect is not observed in all patients and is universally only transient. Determinants of the response to radiotherapy have yet to be defined. We ...

BMP and MAPK Inhibition

We and others co-discovered the presence of activating mutations in ACVR1 in 25% of human DIPGs in 2014. Subsequently, my laboratory has developed a murine DIPG model incorporating R206H ACVR1 and observed that R206H ACVR1 significantly accelerates brainstem gliomagenesis. In addition, short-term treatment with a bone morphogenetic protein pathway inhibitor (...

Defining the molecular mechanisms of DIPG development and progression to ...

  Diffuse Intrinsic Pontine Gliomas (DIPGs) are devastating pediatric brainstem tumors that lack effective treatment and are uniformly fatal. Patient studies have identified recurrent genetic lesions that drive the development of these tumors. Almost all DIPGs carry mutations in genes encoding either replication-dependent histone-H3 proteins (mostly HIST1H3B) or ...